Cancer drug development halted following trial deaths
Mirna Therapeutics Inc. (Austin, TX, USA) halts drug development of its flag-ship oncology drug MRX34 following adverse trial results, culminating with the deaths of clincal trial participants.
Please sign in or register for FREE
Sign in to RxNet
Register to RxNet
RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.